Analysis reveals R&D influences valuation and green bonds reduce WACC, indicating governance in sustainability efforts.
This study tests whether labeled green and sustainability-linked financing complements firms’ R&D to lower the weighted average cost of capital (WACC), raise valuation, and shift innovation toward climate mitigation technologies. Using a 2012–2024 panel of S&P 500 constituents with complete coverage, this study applies a staggered-adoption difference-in-differences design with interaction-weighted event-time estimators and entropy balancing; WACC is decomposed into equity and debt components, valuation is measured by Tobin’s Q, and innovation outcomes cover patent counts and the CPC Y02 share, with matched-bond and secondary-market comparisons for the debt channel. Within two years of first-time adoption, this study observes a meaningful decline in WACC (approximately 40–60 bp) driven mainly by the cost of debt, alongside higher valuation and increased innovation intensity with a larger Y02 share. Effects are larger where R&D intensity is higher and are strongest for use-of-proceeds green bonds and for sustainability-linked contracts with material KPIs and non-trivial step-ups. These results indicate that labeled financing is most effective when aligned with credible R&D pipelines and verification mechanisms, clarifying its governance role in corporate sustainability strategies.
No takes yet. Share an insight, caveat, or question.
Mohammed Naif Alshareef (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: